"Stepped back, took a look, saw a pimple on an elephants arse....just saying."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice close on FTER, I reckon if NITE had not stepped in those .16's might have been gone, no? Thin mate, very thin.
Good observation, I was watching it too, and although I called it a fat finger, you are probably correct. .16 was next in line on the ask and it went there. For a second I thought, dang, this thing is going to run then of course NITE stepped in, if not those .16's would have been taken out too.
The key is right here: “We were extremely pleased with our fourth quarter Cobroxin sales, especially given its initial limited retail availability,” explained Rik J Deitsch
All those sales were just internet and maybe some catalogue. With the 40,000 retail stores getting "into the cycle", Nyloxin, international markets, (maybe even military as there is a connection) etc, this current quarter we should see explosive sales.
BTW, if you have never heard CEO Rik Deitsch speak it is worth the time. Very smart man.
Cobroxin, tried and tested and living pain free for four months now.
Later.
What is a "big board"? LOL, where have you been hanging out?
Horse manure, you participated to see if any of the meds would give you a high!
Good day Blondie, just checking in on my one-eighties, keep up the "Good" work mate. No pun intended.
Great post, to tell you the truth I added as well here, not as much as you though.
Sweeeeeeeeeet!
NPHC closed at HOD .48. Double bottom in mid January, hopefully rally time now.
Where do you get those spread sheets? Thanks in advance.
Your welcome mate, and good luck. Transferring the leftovers to my LT account and will check them out in the years to come. eom
Thanks mate, got to take lumps along the way. I took it and stuck it straight into NPHC and FTER this morning got back 20% already (on both). Sell your losers and let the winners run.
Later.
Great day. eom
Was right there with you mate, added some nice chunks all day long on some nice fat NPHC profits. Lots of dry powder and I will put in support when and if I have to to protect my fairly big position.
.12 up.....
oops edit fat finger.
Thanks mate and good luck I will take a look. eom
super thin.
Sorry, dumped 60% of my shares, that was my mental stop loss limit the other 40% can for all I care rot away there now. Chewing on lumps now, but it feels better. eom
Dang, just saw that .006 and was in the process of putting in a buy order then ask it jumped back to .0075 maybe I should put in a support there. eom
Thanks mate. eom
Nice move, I just never got filled at my target..............oh well.
LOL, I could call them something but that will land me in IBUB jail...........
Because of the long time everyone had to accumulate down in the 30's could mean there will be a more gradual climb as to wild swings as there is some profit taking on the way up. But then again I would not say no to a violent upward move in price either.............. IMO only
There she goes, nicely now........double bottom confirmed, called on 15 January.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45550423
Sometimes the blind squirrel gets the nut if you know what I mean Mate in NC?
Well I hope it holds this support here at about .096. eom
If you all did you DD there is so much other updates and news pending........
NPHC new high of the day .439 up 15.5% on impressive volume of 766K shares. eom
why just that number 2 months in advance of all of the rest of the financials? To keep you on the edge of your seat and biting your nails mate!
Anyone getting a whiff of bad news here? I do not like this bid sitting @ .095. TIA
Forterus, Inc. (OTCBB: FTER) Jumping On Impresive Financial Report
http://www.hotstocked.com/article/1858/forterus-inc-otcbb-fter-jumping-on-impresive.html
No. But you did right? At a loss, no? See you in six months at the top. eom
Flawed! They are definatly not selling the product for $19 per unit to XCHO. Where do you get that figure? That is the retail price. Get your facts right. eom
Well guess I will buy back in around .03-.04 talk to everyone in a couple of weeks..
You let me know when you get it @.03. LOL and good luck to you.
Forterus Company Update just out: http://ih.advfn.com/p.php?pid=nmona&article=41359990&symbol=USOTC:FTER&cb=1265122366
Two form t trades just went through @.40 Edit make that three. eom
Sweet, keep us updated. Thanks in advance.
Now we can start adding in those 40,000 stores into this quarters sale, looking for an absolute explosion in sales numbers at the end of this Q.
NPHC news of sales just hit the wires.
Nutra Pharma Announces Fourth Quarter Sales for Its Over-the-Counter (OTC) Pain Reliever, Cobroxin
http://ih.advfn.com/p.php?pid=nmona&article=41358956&symbol=USBB:XCHO&cb=1265119406
Nutra Pharma Announces Fourth Quarter Sales for Its Over-the-Counter (OTC) Pain Reliever, Cobroxin
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009
“We were extremely pleased with our fourth quarter Cobroxin sales, especially given its initial limited retail availability,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “With the positive feedback we have received from Cobroxin consumers and retailers, we remain optimistic about the future growth of Cobroxin as we move into 2010,” he added
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which began selling in mid-October 2009, is currently available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis
Cobroxin’s additional benefits include:
All Natural
Non-Addictive
Non-Narcotic
Non-Opiate
Long Lasting
Cobroxin is currently sold online and through brick-and-mortar retailers and is distributed by XenaCare Holdings (OTCBB: XCHO), a consumer products company, which is licensed to market and distribute Cobroxin throughout the United States
About Nutra Pharma Corp. Nutra Pharma Corporation (the “Company”) operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company’s wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with
http://www.NutraPharma.com http://www.Cobroxin.com Disclaimer This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above statements pertaining to Cobroxin sales for the fourth quarter of 2009 should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement
Confirmed!! “We were extremely pleased with our fourth quarter Cobroxin sales, especially given its initial limited retail availability,”